Trial Profile
A Single-Center, Open-Label Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2020
Price :
$35
*
At a glance
- Drugs Belapectin (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Sponsors Galectin Therapeutics
- 31 Jul 2018 Status changed from recruiting to completed.
- 31 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 31 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.